GlassScriptPhysician profile
Stefano Emili
NPI 1558319434
$1,653.86
in general payments reported to CMS, 2019-2025
20 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $141 · 2021: $163 · 2022: $399 · 2023: $200 · 2024: $366 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $334.92 | 2023-2025 | |
| Pfizer INC. | $218.68 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $156.17 | 2019-2022 | |
| Amgen INC. | $133.92 | 2024 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $126.07 | 2019-2025 | Voyxact, Jynarque |
| Teleflex LLC | $118.41 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.03 | 2021-2022 | |
| Horizon Therapeutics Plc | $87.18 | 2021-2023 | Krystexxa |
| Travere Therapeutics, INC. | $86.92 | 2019-2025 | |
| Fresenius USA Marketing, INC. | $47.66 | 2019-2024 | Velphoro, Korsuva |
| Ardelyx, INC. | $47.59 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $40.56 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $39.26 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $25.31 | 2025 | Ultomiris |
| Baxter Healthcare | $24.39 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $16.93 | 2023 | Tarpeyo |
| Janssen Pharmaceuticals, INC | $16.37 | 2022 | |
| Mallinckrodt Hospital Products INC. | $15.38 | 2023 | Terlivaz |
| Vifor Pharma, INC. | $14.63 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefano Emili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.